Otsuka Licenses Pre-Phase III Topical Atopic Dermatitis Drug to Medimetriks
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical Co. Ltd. of Japan has licensed US-based Medimetriks Pharmaceuticals, Inc. exclusive development, manufacturing and commercialization rights for its non-steroidal transdermal phosphodiesterase 4 (PDE4) inhibitor OPA-15406 for the US and Puerto Rico to treat atopical dermatitis.